CA3234615A1 - Modified proteins and protein degraders - Google Patents

Modified proteins and protein degraders Download PDF

Info

Publication number
CA3234615A1
CA3234615A1 CA3234615A CA3234615A CA3234615A1 CA 3234615 A1 CA3234615 A1 CA 3234615A1 CA 3234615 A CA3234615 A CA 3234615A CA 3234615 A CA3234615 A CA 3234615A CA 3234615 A1 CA3234615 A1 CA 3234615A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
optionally substituted
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234615A
Other languages
English (en)
French (fr)
Inventor
Jing Liu
Michael Bruno Plewe
Xiaoran HAN
Chengwei Zhang
Ting Yang
Liqun Chen
Matthew Randolph Lee
Jing Zhou
Jie Ding
Jialiang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullgen Shanghai Inc
Original Assignee
Cullgen Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullgen Shanghai Inc filed Critical Cullgen Shanghai Inc
Publication of CA3234615A1 publication Critical patent/CA3234615A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3234615A 2021-10-14 2022-10-13 Modified proteins and protein degraders Pending CA3234615A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021123848 2021-10-14
CNPCT/CN2021/123848 2021-10-14
CNPCT/CN2021/133363 2021-11-26
CN2021133363 2021-11-26
PCT/CN2022/125080 WO2023061440A1 (en) 2021-10-14 2022-10-13 Modified proteins and protein degraders

Publications (1)

Publication Number Publication Date
CA3234615A1 true CA3234615A1 (en) 2023-04-20

Family

ID=85987275

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234615A Pending CA3234615A1 (en) 2021-10-14 2022-10-13 Modified proteins and protein degraders

Country Status (9)

Country Link
US (1) US20250235543A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537394A (cg-RX-API-DMAC7.html)
CN (1) CN118451078A (cg-RX-API-DMAC7.html)
AU (1) AU2022362494A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234615A1 (cg-RX-API-DMAC7.html)
IL (1) IL312013A (cg-RX-API-DMAC7.html)
MX (1) MX2024004525A (cg-RX-API-DMAC7.html)
WO (1) WO2023061440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2024072794A1 (en) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions
CN121005703A (zh) * 2024-05-24 2025-11-25 中国科学院广州生物医药与健康研究院 一种酰胺吲嗪类化合物及其制备方法和应用
WO2026107421A1 (en) * 2024-11-18 2026-05-21 Bristol-Myers Squibb Company 1 h-benzo[d]imidazole derivatives as camk2 inhibitors for the treatment of heart failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201522337A (zh) * 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並-嘧啶化合物類
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US11191741B2 (en) * 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CA3103185A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2020092662A1 (en) * 2018-11-02 2020-05-07 The Wistar Institute Of Anatomy And Biology Proteolysis-targeting chimeras
EA202192260A1 (ru) * 2019-02-15 2021-12-17 Инсайт Корпорейшн Биомаркеры циклин-зависимой киназы 2 и их применение
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
JP2022529700A (ja) * 2019-04-23 2022-06-23 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド サイクリン依存性キナーゼ12(cdk12)の分解剤およびその使用
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
WO2021061151A1 (en) * 2019-09-27 2021-04-01 Romark Laboratories L.C. Screening for anti-hepatitis b compounds
CN114502534A (zh) * 2019-09-30 2022-05-13 协和麒麟株式会社 Bet降解剂
WO2021239117A1 (en) * 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
TW202423914A (zh) * 2022-08-19 2024-06-16 美商凱麥拉醫療公司 Cdk2降解劑及其用途
US20240174665A1 (en) * 2022-08-19 2024-05-30 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
CN118451078A (zh) 2024-08-06
AU2022362494A1 (en) 2024-05-23
EP4416145A4 (en) 2026-05-27
MX2024004525A (es) 2024-05-24
WO2023061440A1 (en) 2023-04-20
JP2024537394A (ja) 2024-10-10
IL312013A (en) 2024-06-01
EP4416145A1 (en) 2024-08-21
US20250235543A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
ES3011855T3 (en) Tyk2 inhibitors and uses thereof
AU2021201536A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) Heteroaromatic compounds useful for the treatment of proliferative diseases
ES2948782T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
CN106660987B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
US9556171B2 (en) Certain protein kinase inhibitors
US20250235543A1 (en) Modified proteins and protein degraders
CA2882733A1 (en) Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents
CA2927920A1 (en) Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2006283592A1 (en) Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008109154A1 (en) Chemokine receptor modulators
CA2954060A1 (en) Inhibitors of lysine specific demethylase-1
CN109071552A (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
CA3171187A1 (en) Inhibitors of ulk1/2 and methods of using same
WO2023283364A2 (en) N,n-dimethyltryptamine and related psychedlics and uses thereof
JP2020143161A (ja) CaMKII阻害剤及びその使用
JP5558470B2 (ja) エピポドフィロトキシンの新規な(ポリ)アミノアルキルアミノアルキルアミド、アルキル−尿素またはアルキル−スルホンアミド誘導体、それらの製造方法、および治療における抗癌剤としてのそれらの応用
WO2016203335A1 (en) Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US20190337902A1 (en) Heterocyclic compounds as hiv protease inhibitors
WO2022226182A1 (en) Nek7 inhibitors
KR20230170684A (ko) Lrrk2 키나제 억제제로서 유용한 피리미딘 유도체
TWI297338B (en) Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
ES2470291T3 (es) Compuestos de bis-arilamida y métodos de uso
CN106660971A (zh) 用于神经退行性疾病和阿尔茨海默病的治疗中的用途的双重抑制剂化合物
HK40105557B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003